Ilginatinib maleate is primarily used in the treatment of myelofibrosis, a type of bone marrow disorder that disrupts the body's normal production of blood cells. It functions as a Janus kinase 2 (JAK2) inhibitor, targeting the JAK-STAT signaling pathway, which is often dysregulated in myeloproliferative neoplasms. By inhibiting this pathway, it helps reduce symptoms such as spleen enlargement, fatigue, and anemia associated with the disease. Additionally, it is being investigated for its potential efficacy in other hematologic malignancies and conditions where JAK2 mutations play a critical role. Its application offers a targeted therapeutic approach, improving quality of life for patients with limited treatment options.